ReviewMedicine2016
Calcineurin Inhibitors Associated Posterior Reversible Encephalopathy Syndrome in Solid Organ Transplantation: Report of 2 Cases and Literature Review.
Review in Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Posterior Reversible Encephalopathy Syndrome in Clinical Toxicology: A Systematic Review of Published Case Reports.Frontiers in neurology · 2019Pooled it
- Article
- Tacrolimus-Induced Atypical Posterior Reversible Encephalopathy Syndrome (PRES) in a Kidney Transplant Recipient: A Case Report.Clinical case reports · 2026Article
- Comparative neuropsychiatric safety signals of tacrolimus versus cyclosporine in solid organ transplantation: ten-year FAERS pharmacovigilance study.Frontiers in immunology · 2026Article
- Article
- A presentation of posterior reversible encephalopathy syndrome after heart transplantation: a case report and review of literature.Journal of medical case reports · 2025Review
- Successful Treatment with Mycophenolate Mofetil in a Patieint with Anti-MDA 5 Antibody-positive Interstitial Lung Disease and Posterior Reversible Encephalopathy Syndrome.Internal medicine (Tokyo, Japan) · 2025Article
- Tacrolimus-Related Posterior Reversible Encephalopathy Syndrome in a Postlung Transplant Patient: A Case Report.Case reports in critical care · 2025Article
- Calcineurin inhibitors-related posterior reversible encephalopathy syndrome in liver transplant recipients: Three case reports and review of literature.World journal of hepatology · 2024Article
- Update on Maintenance Immunosuppression in Intestinal Transplantation.Gastroenterology clinics of North America · 2024Review
- Tacrolimus-Induced Neurotoxicity After Transplant: A Literature Review.Drug safety · 2024Review
- Encephalitis in HIV-negative immunodeficient patients: a prospective multicentre study, France, 2016 to 2019.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024Article
- Escalation to Barbiturate-Induced Coma for Refractory Seizures after Liver Transplantation.Case reports in hepatology · 2022Article
- Late presentation of posterior reversible encephalopathy syndrome following liver transplantation in the setting of tacrolimus and cannabis use.Canadian liver journal · 2022Article
- Fatal Thrombotic Microangiopathy and Posterior Reversible Encephalopathy Syndrome in a Patient with Anti-melanoma Differentiation-associated Gene 5 Antibody-positive Dermatomyositis.Internal medicine (Tokyo, Japan) · 2021Article
- Posterior Reversible Encephalopathy Syndrome Associated with Tacrolimus in Cardiac Transplantation.Case reports in cardiology · 2021Article
- CSA-Induced PRES after Heart Transplantation-Report of Two Cases and Review.The Thoracic and cardiovascular surgeon reports · 2021Article
- Antibody-negative autoimmune encephalitis as a complication of long-term immune-suppression for liver transplantation.BMJ case reports · 2020Article
- Cognitive Function in Kidney Transplantation.Current transplantation reports · 2020Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Posterior reversible encephalopathy syndrome (PRES) is a rare neurologic side effect of calcineurin inhibitors (CNIs) with poorly understood clinical features.We report cases of 2 patients with PRES developing after kidney transplantation and summarize PRES clinical features through a literature review.The 1st case was a 28-year-old man who received a kidney transplant from a deceased donor. Initial immunosuppressive therapy consisted of tacrolimus/mycophenolate mofetil/prednisolone. He developed headache and blurred vision with visual field loss15 days after transplantation and generalized seizures 4 days later. The 2nd case was a 34-year-old man who received a living kidney transplant. His initial immunosuppressive therapy comprised tacrolimus/mycophenolate mofetil/prednisolone. Two months after transplantation, he developed seizures. Both patients were diagnosed with PRES based on neurological symptoms and magnetic resonance imaging (MRI) findings; they recovered after switching from tacrolimus to either a cyclosporine or a lower tacrolimus dose. CNI-associated PRES is an acute neurological syndrome with seizures, encephalopathy, visual abnormalities, headache, focal neurological deficits, and nausea/vomiting. It is always accompanied by hypertension. A fluid-attenuated inversion recovery signal MRI scan typically shows reversible subcortical white matter changes in the posterior cerebral hemisphere that usually occur within the 1st month after transplantation. CNI-associated PRES has a generally favorable prognosis with early diagnosis and prompt treatment including alternating or discontinuing CNIs and blood pressure control.CNI-associated PRES should be considered in patients exhibiting acute neurological symptoms after transplantation. Early diagnosis and immediate treatment are critical for a favorable prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.